Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

ConditionHepatocellular Carcinoma (HCC)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorPalo Alto Veterans Institute for Research

About this trial

The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age > or = 18 years

HCC confirmed on imaging, BCLC stage 0, A, B, or C

Transarterial Y90 radioembolization approved by multidisciplinary tumor board -

Disqualifiers

Not eligible for Y90 procedure

Prior surgery or ablation on indicated tumors

Patient unable to complete the follow up visits required for clinical care or research -

Trial population

Patients at VAPAHCS with HCC

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

Circulating Tumor Cell (CTC)

blood samples

Time frame

Baseline, 1 month post treatment, 3 months post treatment, and 6 months post treatment

CTA imaging

imaging of liver tumor

Time frame

Baseline, 3 months post treatment, 6 months post treatment

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Palo Alto Veterans Institute for Research

Lead sponsor

Source ClinicalTrials.gov

Apply now